Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA4 | P22748 | 6/20 | 0.43 |
| ▸ | CA9 | Q16790 | 6/20 | 0.43 |
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
| ▸ | MC3R | P41968 | 2/20 | 0.39 |
| ▸ | MC1R | Q01726 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009039 | 0.80 | ABCB1 (0.58) | ABCB1CA1CA2CA4CA9 | |
| SCHEMBL20008966 | 0.80 | ABCB1 (0.58) | ABCB1CA1CA2CA4CA9 | |
| SCHEMBL20009037 | 0.80 | ABCB1 (0.58) | ABCB1CA1CA2CA4CA9 | |
| SCHEMBL5539410 | 0.74 | CA1 (0.61) | ABCB1CA1CA2CA4CA9 | |
| SCHEMBL12143612 | 0.71 | ABCB1 (0.62) | ABCB1CA1CA2CA4CA9 | |
| SCHEMBL18081174 | 0.71 | ABCB1 (0.62) | ABCB1CA1CA2CA4CA9 | |
| SCHEMBL12143610 | 0.71 | ABCB1 (0.62) | ABCB1CA1CA2CA4CA9 | |
| SCHEMBL20353482 | 0.71 | CHRM2 (0.50) | KCNH2HRH3KDM4EMEN1KMT2A | |
| SCHEMBL17897292 | 0.70 | CHRM2 (0.49) | HRH3KDM4EMEN1KMT2A | |
| SCHEMBL13225693 | 0.69 | CA2 (0.55) | ABCB1CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | ABCB1 676/4885CA1 4151/4885CA2 3302/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | ABCB1 676/4885CA1 4151/4885CA2 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.